Insulin Detemir: Difference between revisions
Jump to navigation
Jump to search
NCLEX nursing pharmacology monographs — batch import |
Add medication infobox (Drugbox) to monographs |
||
| Line 1: | Line 1: | ||
{{Drugbox | |||
| name = Insulin Detemir | |||
| brand = Levemir | |||
| therapeutic = Antidiabetic | |||
| pharmacologic = Long-acting basal insulin analog | |||
| onset = Onset 1 to 2 hours; minimal peak; duration up to 24 hours (sometimes twice daily). | |||
| halflife = Monitor glucose, not levels. | |||
| routes = SubQ | |||
| highalert = <span style="color:#b00020;">'''Yes'''</span> | |||
| blackbox = None | |||
| antidote = Glucose or glucagon. | |||
| pregnancy = Insulin preferred. | |||
}} | |||
<div style="border-left:4px solid #3f6f5b;background:#f3f6f4;padding:8px 12px;margin-bottom:12px;font-size:0.95em;"> | <div style="border-left:4px solid #3f6f5b;background:#f3f6f4;padding:8px 12px;margin-bottom:12px;font-size:0.95em;"> | ||
''Nursing pharmacology study reference (NCLEX-style monograph). Numeric values are standard teaching ranges for study and '''must be verified against current manufacturer labeling before clinical use'''. This is educational content, not prescribing guidance.'' | ''Nursing pharmacology study reference (NCLEX-style monograph). Numeric values are standard teaching ranges for study and '''must be verified against current manufacturer labeling before clinical use'''. This is educational content, not prescribing guidance.'' | ||
Latest revision as of 16:09, 17 June 2026
| Drug monograph · NCLEX study reference | |
| Trade names | Levemir |
|---|---|
| Therapeutic class | Antidiabetic |
| Pharmacologic class | Long-acting basal insulin analog |
| Onset / peak / duration | Onset 1 to 2 hours; minimal peak; duration up to 24 hours (sometimes twice daily). |
| Half-life / level | Monitor glucose, not levels. |
| Routes | SubQ |
| High-alert (ISMP) | Yes |
| Black box warning | None |
| Antidote / reversal | Glucose or glucagon. |
| Pregnancy / lactation | Insulin preferred. |
Nursing pharmacology study reference (NCLEX-style monograph). Numeric values are standard teaching ranges for study and must be verified against current manufacturer labeling before clinical use. This is educational content, not prescribing guidance.
Insulin Detemir (brand name Levemir) — Antidiabetic; Long-acting basal insulin analog.
Identification
- Therapeutic class: Antidiabetic.
- Pharmacologic class: Long-acting basal insulin analog.
Pharmacology
- Mechanism of action: Basal insulin replacement.
- Onset / peak / duration: Onset 1 to 2 hours; minimal peak; duration up to 24 hours (sometimes twice daily).
- Half-life / therapeutic level: Monitor glucose, not levels.
Clinical use
- Indications: Type 1 and type 2 diabetes.
- Usual dose, route, frequency: SubQ once or twice daily.
- Maximum dose / adjustments: Individualized.
Safety
- Contraindications: Hypoglycemia, hypersensitivity.
- Black box warning: None.
- Interactions: Same insulin interactions.
- Pregnancy / lactation: Insulin preferred.
- High-alert: Yes.
Adverse effects
- Common side effects: Hypoglycemia, injection reactions.
- Serious effects to report: Severe hypoglycemia.
- Antidote / reversal: Glucose or glucagon.
Nursing process
- Assessment before administration: Blood glucose, recent intake.
- Interventions during therapy: Do not mix; rotate sites; double-check per policy.
- Monitor: Blood glucose, A1c.
- Evaluation / expected outcome: Basal glucose control.
Patient teaching
- Patient teaching: Consistent timing; treat lows promptly.
- Notify provider if: Frequent lows or highs.
- Administration tips: SubQ; rotate sites.